These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 22118665)

  • 1. Fighting hepatitis C virus with peptide nanotubes.
    Brik A
    Chem Biol; 2011 Nov; 18(11):1347-8. PubMed ID: 22118665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon.
    Qureshi SA
    Med Res Rev; 2007 May; 27(3):353-73. PubMed ID: 16958135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus (HCV): a review of immunological aspects.
    Irshad M; Khushboo I; Singh S; Singh S
    Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference as a new strategy against viral hepatitis.
    Radhakrishnan SK; Layden TJ; Gartel AL
    Virology; 2004 Jun; 323(2):173-81. PubMed ID: 15193913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enhancement of cellular immune response to DNA vaccine encoding hepatitis C virus core and envelope 2 fusion antigen by murine Fms-like tyrosine kinase 3 ligand].
    Ke JS; Zhao P; Cao J; Yu JP; Qi ZT
    Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):158-62. PubMed ID: 15966314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunology of hepatitis C: clinical significance of T cell response].
    Shin EC
    Korean J Hepatol; 2006 Jun; 12(2):140-53. PubMed ID: 16804339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus entry: an intriguing challenge for drug discovery.
    Meanwell NA
    Curr Opin Investig Drugs; 2006 Aug; 7(8):727-32. PubMed ID: 16955684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.
    Jarczak D; Korf M; Beger C; Manns MP; Krüger M
    FEBS J; 2005 Nov; 272(22):5910-22. PubMed ID: 16279954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with a recombinant fowlpox virus expressing a hepatitis C virus core-E1 polyprotein variant, protects mice and African green monkeys (Chlorocebus aethiops sabaeus) against challenge with a surrogate vaccinia virus.
    Alvarez-Lajonchere L; Amador-Cañizares Y; Frías R; Milian Y; Musacchio A; Guerra I; Acosta-Rivero N; Martínez G; Castro J; Puentes P; Cosme K; Dueñas-Carrera S
    Biotechnol Appl Biochem; 2008 Oct; 51(Pt 2):97-105. PubMed ID: 18215116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies?
    Missale G; Cariani E; Ferrari C
    Dig Liver Dis; 2004 Nov; 36(11):703-11. PubMed ID: 15570998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HCV p7 as a therapeutic target.
    Griffin S
    Curr Opin Investig Drugs; 2010 Feb; 11(2):175-81. PubMed ID: 20112167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers.
    Nakamoto Y; Kaneko S; Takizawa H; Kikumoto Y; Takano M; Himeda Y; Kobayashi K
    J Med Virol; 2003 May; 70(1):51-61. PubMed ID: 12629644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging host cell targets for hepatitis C therapy.
    He Y; Duan W; Tan SL
    Drug Discov Today; 2007 Mar; 12(5-6):209-17. PubMed ID: 17331885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
    Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C.
    Baumert TF; Wellnitz S; Aono S; Satoi J; Herion D; Tilman Gerlach J; Pape GR; Lau JY; Hoofnagle JH; Blum HE; Liang TJ
    Hepatology; 2000 Sep; 32(3):610-7. PubMed ID: 10960457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia.
    Lechmann M; Ihlenfeldt HG; Braunschweiger I; Giers G; Jung G; Matz B; Kaiser R; Sauerbruch T; Spengler U
    Hepatology; 1996 Oct; 24(4):790-5. PubMed ID: 8855177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular virology of the hepatitis C virus: implication for novel therapies.
    Glenn JS
    Clin Liver Dis; 2005 Aug; 9(3):353-69, v. PubMed ID: 16023970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.